{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Lymphocytic+Leukemia&page=9&q=venetoclax", "query": { "condition": "Chronic Lymphocytic Leukemia", "intervention": "venetoclax", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 107, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Lymphocytic+Leukemia&page=10&q=venetoclax&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Lymphocytic+Leukemia&page=8&q=venetoclax&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T23:42:05.255Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03128879", "title": "Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Acalabrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2017-06-16", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-10-23T23:42:05.255Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03128879" }, { "nct_id": "NCT03801525", "title": "Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Ublituximab", "type": "DRUG" }, { "name": "Umbralisib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TG Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 277, "start_date": "2019-05-16", "completion_date": "2022-12-20", "has_results": true, "last_update_posted_date": "2024-04-19", "last_synced_at": "2026-10-23T23:42:05.255Z", "location_count": 50, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 45 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03801525" }, { "nct_id": "NCT02639910", "title": "Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia, Lymphocytic, Chronic, B-Cell", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Tafasitamab", "type": "BIOLOGICAL" }, { "name": "Idelalisib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "MorphoSys AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2016-11", "completion_date": "2021-12", "has_results": true, "last_update_posted_date": "2021-12-20", "last_synced_at": "2026-10-23T23:42:05.255Z", "location_count": 3, "location_summary": "Jacksonville, Florida • Rochester, Minnesota • Columbus, Ohio", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02639910" }, { "nct_id": "NCT04501939", "title": "Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Cirmtuzumab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2020-08-06", "completion_date": "2026-07-22", "has_results": false, "last_update_posted_date": "2025-09-02", "last_synced_at": "2026-10-23T23:42:05.255Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04501939" }, { "nct_id": "NCT02005471", "title": "A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 389, "start_date": "2014-03-17", "completion_date": "2022-08-03", "has_results": true, "last_update_posted_date": "2023-10-17", "last_synced_at": "2026-10-23T23:42:05.255Z", "location_count": 5, "location_summary": "La Jolla, California • Detroit, Michigan • New York, New York + 1 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT02005471" }, { "nct_id": "NCT06846671", "title": "A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "CLL", "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Tacabrutideg", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Idelalisib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2025-04-10", "completion_date": "2030-02-14", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-23T23:42:05.255Z", "location_count": 29, "location_summary": "Jonesboro, Arkansas • Los Angeles, California • San Diego, California + 25 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06846671" }, { "nct_id": "NCT01889186", "title": "A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "17p Deletion", "Cancer of the Blood and Bone Marrow" ], "interventions": [ { "name": "ABT-199 (Main Cohort)", "type": "DRUG" }, { "name": "ABT-199 (Safety Expansion Cohort)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 158, "start_date": "2013-06-27", "completion_date": "2020-12-15", "has_results": true, "last_update_posted_date": "2021-12-16", "last_synced_at": "2026-10-23T23:42:05.255Z", "location_count": 16, "location_summary": "Tucson, Arizona • Duarte, California • La Jolla, California + 11 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01889186" }, { "nct_id": "NCT04285567", "title": "A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia (CLL)" ], "interventions": [ { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 166, "start_date": "2020-05-28", "completion_date": "2025-03-19", "has_results": true, "last_update_posted_date": "2026-03-03", "last_synced_at": "2026-10-23T23:42:05.255Z", "location_count": 4, "location_summary": "Aurora, Colorado • Bethesda, Maryland • Knoxville, Tennessee + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Knoxville", "state": "Tennessee" }, { "city": "Roanoke", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04285567" }, { "nct_id": "NCT06428019", "title": "A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 170, "start_date": "2024-08-05", "completion_date": "2028-03", "has_results": false, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-10-23T23:42:05.255Z", "location_count": 32, "location_summary": "Tucson, Arizona • Clovis, California • Los Angeles, California + 28 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Clovis", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06428019" }, { "nct_id": "NCT07711327", "title": "Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy", "overall_status": "NOT_YET_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Atrial Fibrillation (AF)", "Chronic Lymphocytic Leukemia", "Waldenstrom Macroglobulinemia", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma" ], "interventions": [], "intervention_types": [], "sponsor": "Tina Baykaner", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2026-08", "completion_date": "2031-08", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-10-23T23:42:05.255Z", "location_count": 3, "location_summary": "Duarte, California • San Diego, California • Stanford, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07711327" } ] }